Shiga‐like toxin I exerts specific and potent anti‐tumour efficacy against gastric cancer cell proliferation when driven by tumour‐preferential Frizzled‐7 promoter. (6th April 2019)

• Record Type: Journal Article
• Authors: Xu, Hongpan; Peng, Lijun; Shen, Mengjiao; Xia, Yanyan; Li, Zhiyang; He, Nongyue
• Is Part Of: Cell proliferation. Volume 52:Number 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-04-06
• Subjects: cell proliferation -- Frizzled‐7 -- gastric cancer -- globotriaosylceramide -- Shiga‐like toxin I; Cell proliferation -- Periodicals; 571.84
• DOI: 10.1111/cpr.12607
• Languages: English
• ISSNs: 0960-7722

Abstract

Abstract: Objectives: Tumour‐targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour‐targeting promoters with cytotoxins. Methods: The expression of globotriaosylceramide (Gb3), which is a Shiga‐like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed the recombinant pFZD7‐Stx1 plasmid vectors with tumour‐preferential Frizzled‐7 promoter and Stx1. pFZD7‐Stx1 was used to treat gastric cancer in vitro and in vivo. The gastric cancer cell proliferation and tumour growth were identified after the transfection with the pFZD7‐Stx1. Results: Globotriaosylceramide was obviously increased in gastric cancer compared with normal stomach. The gastric cancer cell proliferation and tumour growth decreased significantly after the transfection with the pFZD7‐Stx1. Conclusion: Frizzled‐7 promoter is preferentially active, and Gb3 is abundant in gastric cancer cells. Frizzled‐7 promoter and Stx1 may be used to determine a novel and relatively specific and potent gastric cancer therapeutic strategy.